ACTG

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2006, for Acacia Research Corporation. The company operates as a single legal entity with two distinct operating groups: the Acacia Technologies Group, which acquires, licenses, and enforces patented technologies, and the CombiMatrix Group, a life sciences division focused on drug development, genetic analysis, and molecular diagnostics. The company maintains two classes of common stock (AR-Acacia Technologies and AR-CombiMatrix) intended to reflect the separate performance of these groups, though both classes are subject to the consolidated liabilities of the parent company.

Key Financial Metrics (Year Ended Dec 31, 2006)

Note: The CombiMatrix Group reported a significant non-cash warrant gain of $1.8 million in 2006, which reduced its reported net loss. Excluding this gain, the operating loss was significantly higher.

Material Changes vs. Prior Period

• Revenue Growth (Acacia Technologies): License fee revenues increased 78% to $34.8 million from $19.6 million in 2005. This growth was driven by the 2005 acquisition of Global Patent Holdings (GPH) and the execution of 126 new licensing agreements in 2006.
• Revenue Decline (CombiMatrix): Revenues decreased to $5.7 million from $8.0 million in 2005. The decline was primarily due to the completion of a $2.3 million collaboration agreement with Toppan in late 2005 and lower activity on Department of Defense (DoD) contracts compared to the previous year.
• Expense Increases: Operating expenses rose significantly for both groups. The Acacia Technologies Group saw increased legal fees and inventor royalties tied to higher revenues. The CombiMatrix Group saw increased Research and Development (R&D) expenses ($9.5 million vs. $5.8 million in 2005) due to the launch of its molecular diagnostics subsidiary (CMDX) and the adoption of SFAS No. 123R (stock-based compensation accounting).
• Impairment Charges: The Acacia Technologies Group recorded a $297,000 non-cash charge for the write-off of a patent-related intangible asset in June 2006. The CombiMatrix Group recorded no impairment charges in 2006, compared to a $565,000 goodwill impairment in 2005.

Guidance, Outlook, and Risks

• CombiMatrix Split-Off: The Board approved a plan to spin off CombiMatrix Corporation into an independent public company, expected to be completed no sooner than the second quarter of 2007. A Form S-1 registration statement was filed in December 2006.
• Liquidity Concerns (CombiMatrix): Management anticipates that the CombiMatrix Group's cash resources will be sufficient only through December 31, 2007. The filing explicitly states that the group will require additional external capital to sustain operations beyond this date. The auditor's report includes a "going concern" qualification for the CombiMatrix Group.
• Liquidity (Acacia Technologies): The Acacia Technologies Group is projected to have sufficient cash resources through at least March 2008.
• Legal Proceedings: The Acacia Technologies Group is engaged in numerous patent enforcement litigations (e.g., against Microsoft, Dell, Comcast, and various retailers). The outcome of these cases is uncertain and could materially impact future revenues. The CombiMatrix Group is facing a whistleblower complaint filed with the Department of Labor by a former executive, which management believes lacks merit.
• Regulatory Risks: The CombiMatrix Group's diagnostic services are subject to FDA regulations. While the FDA indicated in late 2006 that certain tests did not require pre-market approval, future products may require clearance, creating potential delays.

Key Facts for Investor Verification

• Going Concern Status: Verify the CombiMatrix Group's ability to secure external financing before December 31, 2007, as failure to do so could force significant cost-cutting or cessation of operations.
• Spin-Off Execution: Monitor the progress of the CombiMatrix split-off transaction and the effectiveness of the Form S-1 filing, as this will fundamentally alter the company's capital structure.
• Patent Litigation Outcomes: Track the status of major patent enforcement lawsuits (e.g., DMT technology, Credit Card Fraud, Data Encryption) as these are the primary revenue drivers for the Acacia Technologies Group.
• Stock-Based Compensation Impact: Review the impact of SFAS No. 123R adoption, which significantly increased reported expenses in 2006 for both groups due to the fair-value measurement of stock options.
• Warrant Liability Volatility: Note that the CombiMatrix Group's financial results are heavily influenced by the mark-to-market valuation of redeemable warrants, which created a $1.8 million non-cash gain in 2006.